Evaluation of methods for preserving PTEN antigenicity in stored paraffin sections

Applied Immunohistochemistry and Molecular Morphology

Volumn 19, Issue 6, 2011, Pages 569-573

  Gelb, Arnold B ^a   Freeman, Vicki A ^a   Astrow, Stephanie H ^a  

^a QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

Author keywords

antigenicity; IHC; immunohistochemistry; PTEN; stability; storage

Indexed keywords

PARAFFIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ANTIGENICITY; ARTICLE; BREAST CANCER; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CRYOPRESERVATION; CYTOPLASM; FREEZING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; ROOM TEMPERATURE; SIGNAL TRANSDUCTION; TISSUE SECTION;

BIOMARKERS, PHARMACOLOGICAL; BREAST NEOPLASMS; CARCINOMA; CRYOPRESERVATION; DOWN-REGULATION; ENZYME INHIBITORS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; ONCOGENE PROTEIN V-AKT; PARAFFIN EMBEDDING; PHOSPHATIDYLINOSITOL 3-KINASE; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; SPECIMEN HANDLING;

EID: 81755179428     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/PAI.0b013e318217a3d3     Document Type: Article

References (20)

1. Paez J, Sellers WR. PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling. Cancer Treat Res. 2003;115:145-167.
2. Saal LH, Johansson P, Holm K, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci U S A. 2007;104:7564-7569. (Pubitemid 47185946)
3. Eichhorn PJ, Gili M, Scaltriti M, et al. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res. 2008;68:9221-9230.
4. Sherman ME, Howatt W, Blows FM, et al. Molecular pathology in epidemiologic studies: a primer on key considerations. Cancer Epidemiol Biomarkers Prev. 2010;19:966-972.
5. Henson DE. Loss of p53-immunostaining intensity in breast cancer. J Natl Cancer Inst. 1996;88:1015-1016.
6. Jacobs TW, Prioleau JE, Stillman IE, et al. Loss of tumor marker-immunostaining intensity on stored paraffin slides of breast cancer. J Natl Cancer Inst. 1996;88:1054-1059. (Pubitemid 26260491)
7. Bertheau P, Cazals-Hatem D, Meignin V, et al. Variability of immunohistochemical reactivity on stored paraffin slides. J Clin Pathol. 1998;51:370-374. (Pubitemid 28289123)
8. van den Broek LJCM, van de Vijver MJ. Assessment of problems in diagnostic and research immunohistochemistry associated with epitope instability in stored paraffin sections. Appl Immunohistochem Mol Morphol. 2000;8:316-321.
9. Vis AN, Krasne R, Nigg AL, et al. Quantitative analysis of the decay of immunoreactivity in stored prostate needle biopsy sections. Am J Clin Pathol. 2000;113:369-373. (Pubitemid 30217384)
10. Wester K, Wahlund E, Sundström C, et al. Paraffin section storage and immunohistochemistry. Effects of time, temperature, fixation, and retrieval protocol with emphasis on p53 protein and MIB1 antigen. Appl Immunohistochem Mol Morphol. 2000;8:61-70. (Pubitemid 30152356)
11. DiVito KA, Charette LA, Rimm DL, et al. Long-term preservation of antigenicity on tissue microarrays. Lab Invest. 2004;84: 1071-1078. (Pubitemid 39025041)
12. Fergenbaum JH, Montserrat GC, Hewitt SM, et al. Loss of antigenicity in stored sections of breast cancer tissue microarrays. Cancer Epidemiol Biomarkers Prev. 2004;13:667-672. (Pubitemid 38737907)
13. Mirlacher M, Kasper M, Storz M, et al. Influence of slide aging on results of translational research studies using immunohistochemistry. Mod Pathol. 2004;17:1414-1420. (Pubitemid 39472998)
14. Burford HN, Adams AL, Hameed O. Effect of storage on p63 immunohistochemistry. Appl Immunohistochem Mol Morphol. 2009;17:68-71.
15. Blind C, Koepenik A, Pacyna-Gengelbach M, et al. Antigenicity testing by immunohistochemistry after tissue oxidation. J Clin Pathol. 2008;61:79-83. (Pubitemid 351158230)
16. Sakr RA, Barbashina V, Morrogh M, et al. Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffinembedded human breast carcinoma. Appl Immunohistochem Mol Morphol. 2010;18:371-374.
17. McCarty KS Jr, Miller LS, Cox EB, et al. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies. Arch Pathol Lab Med. 1985;109:716-721. (Pubitemid 16237466)
18. Perren A, Weng LP, Boag AH, et al. Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast. Am J Pathol. 1999;155:1253-1260. (Pubitemid 29488932)
19. Gori S, Sidoni A, Colozza M, et al. EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. Ann Oncol. 2009;20:648-654.
20. Hayatt MA. Microscopy, Immunohistochemistry, and Antigen Retrieval Methods for Light and Electron Microscopy. New York: Kluwer Academic; 2002:87.